Algeta's Alpharadin results even better than expected, analysis shows
This article was originally published in Scrip
Executive Summary
Algeta has completed survival analysis on updated clinical data generated from the hugely successful ALSYMPCA Phase III trial of Alpharadin (radium-223 chloride), and concluded that the drug works even better than earlier data showed.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.